▪ **Probabilities of Primary Endpoint Event**^{‡} | | | |

** ***□ FRS >10%* | ** ** | ** ** | ** ** |

– Probability of primary endpoint event | | | |

** *** Statin group* | ** ***...* | ** ***0.0031 (0.0024-0.0037)* | ** ***Ridker*^{§} (Author assumption) |

Standard management group | ... | 0.0054 (0.0043-0.0065) | Ridker^{§} (Author assumption) |

** ***□ FRS ≤10%* | ** ** | ** ** | ** ** |

– Probability of primary endpoint event | | | |

** *** Statin group* | ** ***...* | ** ***0.0011 (0.0009-0.0013)* | ** ***Ridker*^{§} (Author assumption) |

Standard management group | ... | 0.0020 (0.0016-0.0024) | Ridker^{§} (Author assumption) |

** ***– Probability of adverse event*^{∥} | ** ***...* | ** ***0.014 (0.008-0.02)* | ** ***AstraZeneca***23** (Author assumption) |

▪ **Costs, mean** | | | |

** ***□ Outpatient costs, statin group* | ** ** | ** ** | ** ** |

– Office visit (CPT 99213) | ... | $61.31 | CMS^{24} |

** ***– Lipid panel* | ** ***...* | ** ***$19.01* | ** ***CMS*^{25} |

– Alanine aminotransferase | ... | $10.44 | CMS^{25} |

** ***– Asparate aminotransferase* | ** ***...* | ** ***$10.20* | ** ***CMS*^{25} |

– hs-CRP | ... | $25.55 | CMS^{25} |

** ***– Venipuncture* | ** ***...* | ** ***$3.00* | ** ***CMS*^{25} |

–Total initial outpatient cost^{¶} | ... | $129.51 ($103.61-$155.41) | ^{¶} (Author assumption) |

** ***– Total incremental outpatient cost*^{#} | ** ***...* | ** ***$32.38 ($25.90-$38.85)* | ** **^{#} (Author assumption) |

□ Outpatient costs, standard management group | | | |

** ***– Office visit (CPT 99213)* | ** ***...* | ** ***$61.31* | ** ***CMS*^{24} |

– Lipid panel | ... | $19.01 | CMS^{25} |

** ***– hs-CRP* | ** ***...* | ** ***$25.55* | ** ***CMS*^{25} |

– Venipuncture | ... | $3.00 | CMS^{25} |

** ***– Total initial outpatient cost*^{¶} | ** ***...* | ** ***$108.87 ($87.10-$130.64)* | ** **^{¶} (Author assumption) |

– Total incremental outpatient cost^{#} | ... | $27.22 ($21.77-$32.66) | ^{#} (Author assumption) |

** ***□ Other costs* | ** ** | ** ** | ** ** |

– Rosuvastatin, 20 mg/tablet | ... | $4.11 ($0.13-$5.00) | Red Book^{23} (Author assumption) |

** ***– Primary endpoint event* | ** ***...* | ** ***$13,123 ($5397-$26,770)* | ** ***** (Author estimate)* |

– Nonfatal myocardial infarction | 0.14 | $6891.39 ($4459.66-$9951.16) | CMS^{26}^{,}^{27} (Author estimate) |

** ***– Nonfatal stroke* | ** ***0.19* | ** ***$7973.14 ($4327.86-$14,727.25)* | ** ***CMS*^{26}^{,}^{27} (Author estimate) |

– Arterial revascularization | 0.45 | $20,581.76 ($9809.11-$39,200.54) | CMS^{26}^{,}^{27} (Author estimate) |

** ***– Hospitalization for unstable angina* | ** ***0.10* | ** ***$2549.85 ($2039.88-$3059.82)* | ** ***CMS*^{26}^{,}^{27} (Author estimate) |

– Death from cardiovascular causes | 0.12 | $7599.23 ($0.00-$39,200.54) | ^{††} (Author estimate) |

** ***▪ ***Health Utilities**^{‡‡} | ** ** | ** ** | ** ** |

□ Primary endpoint event | ... | 0.606 (0-1) | ** |

** ***□ Nonfatal myocardial infarction* | ** ***0.14* | ** ***0.704* | ** ***Sullivan and Ghushchyan*^{28} |

□ Nonfatal stroke | 0.19 | 0.650 | Sullivan and Ghushchyan^{28} |

** ***□ Arterial revascularization* | ** ***0.45* | ** ***0.6995* | ** ***Author estimate* |

□ Hospitalization for unstable angina | 0.10 | 0.695 | Sullivan and Ghushchyan^{28} |

** ***□ Death from cardiovascular causes* | ** ***0.12* | ** ***0* | ** ***Author assumption* |

□ Healthy/no event | ... | 1.00 (0.90-1.00) | Author assumption |